These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37558302)

  • 1. Calcium Release Deficiency Syndrome: A New Inherited Arrhythmia Syndrome.
    Kallas D; Roberts JD; Sanatani S; Roston TM
    Card Electrophysiol Clin; 2023 Sep; 15(3):319-329. PubMed ID: 37558302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome.
    Roston TM; Wei J; Guo W; Li Y; Zhong X; Wang R; Estillore JP; Peltenburg PJ; Noguer FRI; Till J; Eckhardt LL; Orland KM; Hamilton R; LaPage MJ; Krahn AD; Tadros R; Vinocur JM; Kallas D; Franciosi S; Roberts JD; Wilde AAM; Jensen HK; Sanatani S; Chen SRW
    JAMA Cardiol; 2022 Jan; 7(1):84-92. PubMed ID: 34730774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome.
    Ormerod JOM; Ormondroyd E; Li Y; Taylor J; Wei J; Guo W; Wang R; Sarton CNS; McGuire K; Dreau HMP; Taylor JC; Ginks MR; Rajappan K; Chen SRW; Watkins H
    Circ Genom Precis Med; 2022 Feb; 15(1):e003589. PubMed ID: 34949103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac ryanodine receptor calcium release deficiency syndrome.
    Sun B; Yao J; Ni M; Wei J; Zhong X; Guo W; Zhang L; Wang R; Belke D; Chen YX; Lieve KVV; Broendberg AK; Roston TM; Blankoff I; Kammeraad JA; von Alvensleben JC; Lazarte J; Vallmitjana A; Bohne LJ; Rose RA; Benitez R; Hove-Madsen L; Napolitano C; Hegele RA; Fill M; Sanatani S; Wilde AAM; Roberts JD; Priori SG; Jensen HK; Chen SRW
    Sci Transl Med; 2021 Feb; 13(579):. PubMed ID: 33536282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current management of inherited arrhythmia syndromes associated with the cardiac ryanodine receptor.
    Przybylski R; Abrams DJ
    Curr Opin Cardiol; 2023 Jul; 38(4):390-395. PubMed ID: 37016946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights on the mechanism of flecainide in catecholaminergic polymorphic ventricular tachycardia.
    Davidson R; Medeiros M
    J Med Life; 2023 Aug; 16(8):1294-1296. PubMed ID: 38024821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene.
    Nof E; Belhassen B; Arad M; Bhuiyan ZA; Antzelevitch C; Rosso R; Fogelman R; Luria D; El-Ani D; Mannens MM; Viskin S; Eldar M; Wilde AA; Glikson M
    Heart Rhythm; 2011 Oct; 8(10):1546-52. PubMed ID: 21699856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flecainide in patient with aggressive catecholaminergic polymorphic ventricular tachycardia due to novel RYR2 mutation.
    Wangüemert-Pérez F; Ruiz-Hernández PM; Campuzano O; Caballero-Dorta E; Bosch C; Brugada J; Brugada R
    Minerva Cardioangiol; 2014 Aug; 62(4):363-6. PubMed ID: 25012103
    [No Abstract]   [Full Text] [Related]  

  • 9. Identification of loss-of-function RyR2 mutations associated with idiopathic ventricular fibrillation and sudden death.
    Zhong X; Guo W; Wei J; Tang Y; Liu Y; Zhang JZ; Tan VH; Zhang L; Wang R; Jones PP; Napolitano C; Priori SG; Chen SRW
    Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33825858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia.
    Roston TM; Cunningham TC; Sanatani S
    Cardiol Young; 2017 Jan; 27(S1):S49-S56. PubMed ID: 28084961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flecainide Reduces Ventricular Arrhythmias in Patients With Genotype RyR2-positive Catecholaminergic Polymorphic Ventricular Tachycardia.
    Wangüemert Pérez F; Hernández Afonso JS; Groba Marco MDV; Caballero Dorta E; Álvarez Acosta L; Campuzano Larrea O; Pérez G; Brugada Terradellas J; Brugada Terradellas R
    Rev Esp Cardiol (Engl Ed); 2018 Mar; 71(3):185-191. PubMed ID: 28789916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diverse Phenotypic Manifestations in a Family with a Novel RYR2 E4107A Variant.
    Hasegawa H; Tamura S; Nakajima T; Kawabata-Iwakawa R; Kobari T; Matsumoto N; Sano Y; Nishiyama M; Kurabayashi M; Kaneko Y; Nakatani Y; Ishii H
    Int Heart J; 2024; 65(3):580-585. PubMed ID: 38825499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report.
    Seidlmayer LK; Riediger F; Pagonas N; Nordbeck P; Ritter O; Sasko B
    J Med Case Rep; 2018 Oct; 12(1):298. PubMed ID: 30296944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catecholaminergic Polymorphic Ventricular Tachycardia: A Review of Therapeutic Strategies.
    Bergeman AT; Wilde AAM; van der Werf C
    Card Electrophysiol Clin; 2023 Sep; 15(3):293-305. PubMed ID: 37558300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-Phenotype of Left Ventricular Non-Compaction Cardiomyopathy and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia in Association With R169Q, a Ryanodine Receptor Type 2 Missense Mutation.
    Nozaki Y; Kato Y; Uike K; Yamamura K; Kikuchi M; Yasuda M; Ohno S; Horie M; Murayama T; Kurebayashi N; Horigome H
    Circ J; 2020 Jan; 84(2):226-234. PubMed ID: 31875585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel cardiac ryanodine receptor gene (RyR2) mutation in an athlete with aborted sudden cardiac death: a case of adult-onset catecholaminergic polymorphic ventricular tachycardia.
    Arakawa J; Hamabe A; Aiba T; Nagai T; Yoshida M; Touya T; Ishigami N; Hisadome H; Katsushika S; Tabata H; Miyamoto Y; Shimizu W
    Heart Vessels; 2015 Nov; 30(6):835-40. PubMed ID: 25092222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy.
    Watanabe H; Knollmann BC
    J Electrocardiol; 2011; 44(6):650-5. PubMed ID: 21872879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
    Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
    Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
    Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC
    Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
    Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L
    Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.